Brief: Sedana Medical Q3 EBIT Loss Widens To SEK 5.1 Mln
Nov 13 (Reuters) - Sedana Medical AB (publ) SEDANA.ST :
* , INTERIM REPORT Q3, 2019
* NET SALES DURING Q3 AMOUNTED TO KSEK 16,416 (12,682)
CORRESPONDING TO AN INCREASE OF 29% COMPARED WITH SAME PERIOD IN
2018
* Q3 EBIT AMOUNTED TO KSEK -5,093 (-2,051)
Source text for Eikon: ID:nWkrbhHpDQ
Further company coverage: SEDANA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Sedana Medical AB (publ)
See all newsSweden's Sedana Medical Q3 sales rise as growth returns
Brief: Sedana Medical Announces PDUFA Target Action Date
Brief: Sedana Medical Announces FDA Acceptance For Review Of Its New Drug Application In U.S.
Sweden's Sedana Medical Q2 sales flat, EBITDA loss narrows
Brief: Sedana Medical Q2 EBITDA Loss Narrows To SEK 1.9 Mln